Home/Filings/4/0001957554-26-000003
4//SEC Filing

Balthaser Kevin 4

Accession 0001957554-26-000003

CIK 0001557746other

Filed

Jan 4, 7:00 PM ET

Accepted

Jan 5, 4:27 PM ET

Size

19.6 KB

Accession

0001957554-26-000003

Insider Transaction Report

Form 4
Period: 2025-12-31
Balthaser Kevin
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-31+73,750166,358 total
  • Tax Payment

    Common Stock

    2025-12-31$3.01/sh19,934$60,001146,424 total
  • Exercise/Conversion

    Common Stock

    2026-01-01+7,500153,924 total
  • Tax Payment

    Common Stock

    2026-01-01$3.01/sh2,250$6,772151,674 total
  • Exercise/Conversion

    Common Stock

    2026-01-02+13,200164,874 total
  • Tax Payment

    Common Stock

    2026-01-02$2.88/sh4,461$12,848160,413 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-12-3173,7500 total
    Common Stock (73,750 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2026-01-017,5007,500 total
    Common Stock (7,500 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2026-01-0213,20013,600 total
    Common Stock (13,200 underlying)
Footnotes (5)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
  • [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
  • [F3]50% of the shares underlying these restricted stock units vested on each of December 31, 2024 and December 31, 2025.
  • [F4]The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
  • [F5]The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

Issuer

Aclaris Therapeutics, Inc.

CIK 0001557746

Entity typeother

Related Parties

1
  • filerCIK 0001957554

Filing Metadata

Form type
4
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 4:27 PM ET
Size
19.6 KB